Digital Repository

The effect of glycaemic control on neutralizing antibody response to COVID-19 among patients with type 2 diabetes mellitus in the Kurunegala district of Sri Lanka; A prospective cohort study

Show simple item record

dc.contributor.author Kottahachchi, D.
dc.contributor.author Badanasinghe, N.
dc.contributor.author Samarathunga, P.
dc.contributor.author Sandeepani, P.
dc.contributor.author Cooray, S.
dc.contributor.author Warnakulasuriya, T.
dc.date.accessioned 2023-10-02T09:15:31Z
dc.date.available 2023-10-02T09:15:31Z
dc.date.issued 2023
dc.identifier.citation Sri Lanka Journal of Diabetes Endocrinology and Metabolism.2023;14(2):14-21 en_US
dc.identifier.issn 2012-998X
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/26601
dc.description Not Indexed en_US
dc.description.abstract BACKGROUND: The antibody response following COVID-19 vaccination among patients with diabetes mellitus (DM) is of particular concern given the increased risk of severe disease in this population. The correlation between glycaemic control among persons with DM and the antibody response was not published in Asian populations. Hence, this study aimed to determine whether glycaemic control has an association with the development of an adequate antibody response for SARS-CoV-2 among patients with DM following the administration of two doses of the COVID-19 vaccine. METHODS: A prospective cohort study was carried out at three vaccination centers in the Kurunegala district from November 2021 to January 2022. Seventy-one patients with type 2 diabetes were recruited for this study and followed up on vaccination with the Sinopharm COVID-19 vaccine. HbA1 c levels at the first dose and after 6-8 weeks from the second dose of vaccine were analyzed. The neutralizing antibodies (NAbs) were analyzed using C Pass™ neutralizing antibody detection ELISA Kit following 6-8 weeks of the 2nd dose. RESULTS: The median (IQR) age of the total population (63.4% females) was 53 years (44.0-58.0) and they were diagnosed with diabetes for 6 years (3-11 years). The median first and second HbAlc values were 9.3% (7.2-10.7%) and 8.2% (7.1-10.2%) respectively. From the total population, only 66.2% developed protective levels of NAbs after 6-8 weeks of the second dose of the vaccine. The second HbAlc value was significantly lower compared to the first (z=-2.63, p=0.008). There was no significant difference in terms of sex, age, duration of diabetes, pre-vaccination HbAlc level, or HbAlc level 6-8 weeks after the vaccination among those who developed protective levels of antibodies and those who did not (p>0.05). There was no difference in sero-conversion depending on the abnormal HbAlc value (.28%) (1st HbAlc p=0.957, 2nd HbAlc p=0.360). Conclusion: We did not detect an association between glycaemic control and sero-conversion. However, 1/3rd of patients with diabetes did not have a protective level of NAbs following 2 doses of Sinopharm COVID-19 vaccination. Furthermore, glycaemic control did not deteriorate with COVID-19 vaccination. en_US
dc.language.iso en en_US
dc.publisher Endocrine Society of Sri Lanka en_US
dc.subject COVID-19 vaccine en_US
dc.subject Sero-conversion en_US
dc.subject Diabetes en_US
dc.subject Neutralizing antibody en_US
dc.title The effect of glycaemic control on neutralizing antibody response to COVID-19 among patients with type 2 diabetes mellitus in the Kurunegala district of Sri Lanka; A prospective cohort study en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account